Cue Biopharma, Inc. CUE

Company Overview

Cue Biopharma, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies designed to selectively modulate disease-relevant T cells. The company operates within the biotechnology and immuno-oncology industries, with additional research activity in autoimmune and inflammatory diseases. Cue Biopharma’s core technology platform, known as the Immuno-STAT platform, is engineered to mimic the body’s natural immune signaling mechanisms in order to activate or regulate specific T-cell populations while potentially reducing systemic toxicity associated with broader immune therapies.

The company’s primary business activities center on the research, development, and commercialization potential of its biologic drug candidates. Its lead programs have historically focused on oncology indications, including human papillomavirus (HPV)-related cancers, while additional programs target autoimmune diseases and other immune-mediated conditions. Cue Biopharma was founded in 2014 and became publicly traded on Nasdaq under the ticker CUE in 2018. The company has positioned itself as a precision immunotherapy developer aiming to differentiate its therapies through selective immune activation and modular biologic engineering.